Fifth Third Wealth Advisors LLC Buys 960 Shares of Bristol-Myers Squibb (NYSE:BMY)

Fifth Third Wealth Advisors LLC raised its stake in Bristol-Myers Squibb (NYSE:BMY) by 6.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,928 shares of the biopharmaceutical company’s stock after purchasing an additional 960 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $901,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Envestnet Asset Management Inc. increased its holdings in shares of Bristol-Myers Squibb by 1.6% during the second quarter. Envestnet Asset Management Inc. now owns 2,268,887 shares of the biopharmaceutical company’s stock valued at $94,227,000 after acquiring an additional 34,643 shares in the last quarter. Citizens Financial Group Inc. RI grew its position in Bristol-Myers Squibb by 29.7% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,203 shares of the biopharmaceutical company’s stock valued at $1,462,000 after purchasing an additional 8,070 shares during the period. Axxcess Wealth Management LLC increased its stake in Bristol-Myers Squibb by 4.6% during the 2nd quarter. Axxcess Wealth Management LLC now owns 76,958 shares of the biopharmaceutical company’s stock valued at $3,196,000 after purchasing an additional 3,404 shares in the last quarter. Wealth Alliance lifted its stake in shares of Bristol-Myers Squibb by 13.8% in the second quarter. Wealth Alliance now owns 44,503 shares of the biopharmaceutical company’s stock valued at $1,848,000 after buying an additional 5,390 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its holdings in shares of Bristol-Myers Squibb by 13.2% during the second quarter. E Fund Management Co. Ltd. now owns 7,190 shares of the biopharmaceutical company’s stock valued at $299,000 after buying an additional 840 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were acquired at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. The trade was a 3.04 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Trading Up 0.4 %

Bristol-Myers Squibb stock opened at $55.96 on Thursday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08. The business’s fifty day moving average is $57.44 and its 200 day moving average is $51.76. The stock has a market capitalization of $113.50 billion, a PE ratio of -15.59, a price-to-earnings-growth ratio of 15.20 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The firm had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the business posted $2.00 earnings per share. On average, sell-side analysts predict that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a $0.62 dividend. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.43%. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -69.08%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BMY shares. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and upped their price objective for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Truist Financial increased their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, Citigroup upped their target price on Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $56.27.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.